U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H31NO3
Molecular Weight 357.4873
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXYBUTYNIN, (R)-

SMILES

CCN(CC)CC#CCOC(=O)[C@](c1ccccc1)(C2CCCCC2)O

InChI

InChIKey=XIQVNETUBQGFHX-QFIPXVFZSA-N
InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H31NO3
Molecular Weight 357.4873
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

PubMed

PubMed

TitleDatePubMed
Tolterodine: a review of its use in the treatment of overactive bladder.
2001
Preformulation studies on the S-isomer of oxybutynin hydrochloride, an Improved Chemical Entity (ICE).
2001 Apr
Combined pharmacotherapy for nocturnal enuresis.
2001 Aug
Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride.
2001 Oct
Augmentation ureterocystoplasty in bladder exstrophy: 5-year follow-up in two cases.
2002 Dec
Oxytrol approved for overactive bladder.
2003 Aug
[Non-coordinated micturition syndrome mimicking posterior urethral valves in a male neonate].
2003 Jul
Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
2003 Jun
Oxybutynin transdermal (Oxytrol) for overactive bladder.
2003 May 12
Acupressure versus oxybutinin in the treatment of enuresis.
2003 Nov-Dec
[Prevalence of urinary incontinence and linked factors in men and women over 65].
2003 Oct 15
Drug approval highlights for 2003.
2004 Feb
Rapid and selective UV spectrophotometric and RP-HPLC methods for dissolution studies of oxybutynin immediate-release and controlled-release formulations.
2004 Nov 15
[Urinary incontinence: anticholinergic treatment].
2004 Oct-Dec
A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation.
2005
High performance liquid chromatographic determination of oxeladin citrate and oxybutynin hydrochloride and their degradation products.
2005 Aug
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Canadian Urological Association guidelines on urinary incontinence.
2006 Jun
Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin.
2006 Oct
Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
2006 Oct
Analysis of pharmacological effects of drugs used for treatment of urinary disturbance based on anticholinergic and smooth muscle-relaxing effects.
2007 Jul
Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin.
2007 Jul 13
Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats.
2007 May
Bladder augmentation: Review of the literature and recent advances.
2007 Oct
A review of urodynamic evaluation in children and its role in the management of boys with posterior urethral valves.
2007 Oct
Intravesical treatments for painful bladder syndrome/ interstitial cystitis.
2007 Oct 17
Primary monosymptomatic nocturnal enuresis in children and adolescents.
2007 Sep
Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
2007 Sep
Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.
2008 Feb 2
Treatment of urinary incontinence after stroke in adults.
2008 Jan 23
Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
2009 Nov
Reversible bilateral optic neuritis after Infliximab discontinuation in a patient with Crohn's disease.
2009 Sep
Oxybutynin extended release for the management of overactive bladder: a clinical review.
2009 Sep 21
Quantitative determination of oxybutynin hydrochloride by spectrophotometry, chemometry and HPTLC in presence of its degradation product and additives in different pharmaceutical dosage forms.
2010 Mar 15
Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence.
2010 Sep 14
Patents
Substance Class Chemical
Created
by admin
on Sat Jun 26 00:10:59 UTC 2021
Edited
by admin
on Sat Jun 26 00:10:59 UTC 2021
Record UNII
5BRQ29UUB7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXYBUTYNIN, (R)-
Common Name English
(-)-OXYBUTYNIN
Common Name English
OXYBUTYNIN, (-)-
Common Name English
(R)-OXYBUTYNIN
Common Name English
BENZENEACETIC ACID, .ALPHA.-CYCLOHEXYL-.ALPHA.-HYDROXY-, 4-(DIETHYLAMINO)-2-BUTYN-1-YL ESTER, (.ALPHA.R)-
Systematic Name English
R-OXYBUTYNIN
Common Name English
Code System Code Type Description
FDA UNII
5BRQ29UUB7
Created by admin on Sat Jun 26 00:10:59 UTC 2021 , Edited by admin on Sat Jun 26 00:10:59 UTC 2021
PRIMARY
CAS
119618-21-2
Created by admin on Sat Jun 26 00:10:59 UTC 2021 , Edited by admin on Sat Jun 26 00:10:59 UTC 2021
PRIMARY
PUBCHEM
6098167
Created by admin on Sat Jun 26 00:10:59 UTC 2021 , Edited by admin on Sat Jun 26 00:10:59 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
RACEMATE -> ACTIVE ENANTIOMER
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY